Journal profile · Immunology and Microbiology-Immunology
npj Vaccines
ISSN 2059-0105 · Springer Nature · United Kingdom · Founded 2016
npj Vaccines: CAS Zone 2 · Medicine (2025 upgraded edition, Top journal); impact factor 7.24; fully open access; APC about USD 4,090; median 147 days to acceptance (102 articles, last 24 months); 301 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
npj Vaccines is published by Springer Nature and is in Zone 2 of Medicine in the CAS Journal Ranking (2025 upgraded edition, Top journal). By OpenAlex counts of its recent articles, its largest topics are SARS-CoV-2 and COVID-19 Research, Immunotherapy and Immune Responses and Influenza Virus Research Studies, together about 26.8% of its articles. Its main subfields are Infectious Diseases. (generated from OpenAlex topic counts and CAS ranking data)
Find out about the journal aims and scope. Supporting the Sustainable Developmental Goals We are proud to acknowledge that over 50% of the articles published in npj Vaccines in 2025 were related to one or more of the 17 Sustainable Development Goals (SDGs). Springer Nature supports the SDGs through a dedicated SDG Programme and is a signatory of the SDG Publishers Compact.
From the journal's Aims & Scope
Research area (LetPub): Immunology and Microbiology-Immunology
Main research topics OpenAlex counts of recent articles; shares are approximate
- SARS-CoV-2 and COVID-19 ResearchMedicine12.4%
- Immunotherapy and Immune ResponsesImmunology and Microbiology7.4%
- Influenza Virus Research StudiesMedicine7.1%
- Mosquito-borne diseases and controlMedicine5.7%
- Respiratory viral infections researchMedicine5.1%
- Viral gastroenteritis research and epidemiologyMedicine5%
- vaccines and immunoinformatics approachesBiochemistry, Genetics and Molecular Biology4.9%
- Viral Infections and VectorsMedicine4.8%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Immunology | Zone 2 |
| Minor | Medicine, Research & Experimental | Zone 2 |
Top journal: yesReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Immunology | Zone 2 |
| Minor | Medicine, Research & Experimental | Zone 2 |
Top journal: yesReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Medicine, Research & Experimental | Zone 1 |
| Minor | Immunology | Zone 2 |
Top journal: noReview journal: no
Database indexing
SCIEScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
Web of ScienceEmbaseCASCAB AbstractsPublisher website
Other: Google Scholar, ProQuest, Dimensions, CNKI, Baidu, Naver, OCLC, Portico, CLOCKSS
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 7.24LetPub ·
- Impact factor (publisher) 2025
- 7.2Publisher website ·
- 5-year impact factor (publisher) 2025
- 6.6Publisher website ·
- CiteScore 2026-06
- 9.8LetPub ·
- SJR 2026-06
- 2.28LetPub ·
- SNIP 2026-06
- 1.43LetPub ·
- h-index
- 8LetPub ·
- h-index
- 83OpenAlex ·
- i10-index
- 823OpenAlex ·
- 2-year mean citedness
- 6.92OpenAlex ·
- Self-citation rate
- 5.6%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 280LetPub ·
- Articles per year (publisher)
- 2,025Publisher website ·
- Downloads per year (publisher) 2025
- 3,901,115Publisher website ·
Articles by year OpenAlex count · 1,584 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 228 | 228 | 193 |
| 2025 | 301 | 301 | 1,723 |
| 2024 | 258 | 258 | 3,529 |
| 2023 | 190 | 190 | 4,682 |
| 2022 | 174 | 174 | 4,680 |
| 2021 | 158 | 158 | 8,126 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
147 daysMedian, submission to acceptance · P25–P75 106 days – 191 days
- Acceptance to online
- median 16 days (102 articles)
- Submission to online
- median 174 days
- Sample
- 102 articles with submission and acceptance dates (607 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 11 weeksLetPub ·
- Desk decision
- 13 daysPublisher website ·
- Submission to publication (journal-reported)
- about 11 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | EUR 3,590 / USD 4,090 / GBP 3,190 | Yes | CC BY, CC BY-NC-ND | |
| OpenAlex | USD 3,890 / EUR 3,490 / GBP 3,090 | — | — | |
| LetPub | GBP 2,990 / USD 3,690 / EUR 3,390 | Yes | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Policy excerpts from the journal's websiteOpen access
- Open access Open Access
npj Vaccines is a fully open access journal. More on Creative Commons Attribution licenses and the benefits of publishing open access can be found in this section.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Springer Nature
- Country or region
- United Kingdom
- Language
- English
- Founded
- 2016
- ISSN
- 2059-0105
- Official links
- Journal homepage ↗LetPub
- Submission system ↗Publisher website
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗LetPub
- Editorial board ↗LetPub
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about npj Vaccines
What CAS zone is npj Vaccines in?
In the 2025 upgraded edition of the CAS Journal Ranking, npj Vaccines is in Zone 2 of Medicine, and in Zone 2 of the minor category Immunology / Medicine, Research & Experimental; it is a Top journal. In the 2026 Xinrui edition it is in Zone 2 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of npj Vaccines?
The latest impact factor listed by LetPub is 7.24; CiteScore 9.8, h-index 83.
How long does peer review take at npj Vaccines?
Based on the dates recorded on 102 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 147 days (interquartile range 106–191 days); authors report an average review time of about 11 weeks. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index npj Vaccines?
According to LetPub and DOAJ records, npj Vaccines is indexed in SCIE, Scopus and DOAJ. The journal's website also lists Web of Science, Embase, CAS and CAB Abstracts; that list has not been checked against each database.
Is npj Vaccines open access, and what is the APC?
npj Vaccines is a fully open-access journal. APC about USD 4,090.
Sources and updates
The facts on this page come from LetPub, OpenAlex, DOAJ, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .